The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Authors

Kenneth C Anderson
Daniel Auclair
Gary J Kelloff
Caroline C Sigman
Herve Avet-Loiseau
Ann T Farrell
Nicole J Gormley
Shaji K Kumar
Ola Landgren
Nikhil C Munshi
Michele Cavo
Faith E Davies
Alessandra Di Bacco
Jennifer S Dickey
Steven I Gutman
Howard R Higley
Mohamad A Hussein
J Milburn Jessup
Ilan R Kirsch
Richard F Little
Robert D Loberg
Jens G Lohr
Lata Mukundan
James L Omel
Trevor J Pugh
Gregory H Reaman, George Washington UniversityFollow
Michael D Robbins
A Kate Sasser
Nancy Valente
Elena Zamagni

Document Type

Journal Article

Publication Date

4-20-2017

Journal

Clinical Cancer Research : An Official Journal of the American Association for Cancer Research

DOI

10.1158/1078-0432.CCR-16-2895

APA Citation

Anderson, K., Auclair, D., Kelloff, G., Sigman, C., Avet-Loiseau, H., Farrell, A., Gormley, N., Kumar, S., Landgren, O., Munshi, N., Cavo, M., Davies, F., Di Bacco, A., Dickey, J., Gutman, S., Higley, H., Hussein, M., Jessup, J., Kirsch, I., Little, R., Loberg, R., Lohr, J., Mukundan, L., Omel, J., Pugh, T., Reaman, G., Robbins, M., Sasser, A., Valente, N., & Zamagni, E. (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, (). http://dx.doi.org/10.1158/1078-0432.CCR-16-2895

Peer Reviewed

1